A2AR antagonist 1
CAS: 443103-97-7
Rif. 3D-TSA10397
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
VIPadenant is a small molecule that has been developed to selectively inhibit the adenosine A2A receptor. It has the ability to modulate immune responses by inhibiting the production of pro-inflammatory cytokines and chemokines in Th17 cells, which are cells that play a role in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. VIPadenant also inhibits lipase activity and blocks adenosine from binding to its receptors, which may lead to an increased metabolism of fat. The drug has shown an ability to inhibit cancer cell proliferation, and has been patented for use as a potential anti-cancer agent.